Showing results (111-120 of 294) with videos related to
Sort By:
Pageof 30
Therapeutic Drug Monitoring|May 22, 2002
NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonatesMatthijs de Hoog, Rik C Schoemaker, John N van den Anker, et al.Therapeutic Drug Monitoring|April 10, 2007
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implicationsNicole A Weimert, Maurits Derotte, Rita R Alloway, et al.British Journal of Clinical Pharmacology|December 22, 2016
Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology GroupTomoyuki Mizuno, Tsuyoshi Fukuda, Uwe Christians, et al.Clinical Pharmacokinetics|December 15, 2010
The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseaseCatherine M T Sherwin, Tsuyoshi Fukuda, Hermine I Brunner, et al.Journal of Clinical Pharmacology|December 31, 2020
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future ApproachesBrooks T McPhail, Chie Emoto, Dawn Butler, et al.Journal of Pharmacokinetics and Pharmacodynamics|June 14, 2011
Optimal study design for pioglitazone in septic pediatric patientsCatherine M T Sherwin, Lili Ding, Jennifer Kaplan, et al.Clinical Pharmacology and Therapeutics|October 10, 2018
Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical StudyDavid Hahn, Chie Emoto, Joshua C Euteneuer, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 20, 2024
Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear BioavailabilityMatthijs W van Hoogdalem, Ryota Tanaka, Trevor N Johnson, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2018
PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small InfantsChie Emoto, Trevor N Johnson, Sibylle Neuhoff, et al.Therapeutic Drug Monitoring|October 22, 2010
Longitudinal comparison of thyroxine pharmacokinetics between pregnant and nonpregnant women: a stable isotope studyOffie P Soldin, Steven J Soldin, Alexander A Vinks, et al.Pageof 30